XNASAVTE
Market cap74mUSD
Jan 17, Last price
2.58USD
1D
6.17%
1Q
8.86%
IPO
-86.71%
Name
Aerovate Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-76m
L+46.61%
CFO
-57m
L+45.13%
Earnings
Jun 05, 2025
Profile
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 81,505 | 53,305 | |||
Unusual Expense (Income) | |||||
NOPBT | (81,505) | (53,305) | |||
NOPBT Margin | |||||
Operating Taxes | 56 | 25 | |||
Tax Rate | |||||
NOPAT | (81,561) | (53,330) | |||
Net income | (75,521) 46.61% | (51,511) 124.32% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 44,888 | 150 | |||
BB yield | -7.53% | -0.02% | |||
| Debt | |||||
Debt current | 840 | 385 | |||
Long-term debt | 930 | 1,795 | |||
Deferred revenue | |||||
Other long-term liabilities | 70 | 71 | |||
Net debt | (120,669) | (127,040) | |||
| Cash flow | |||||
Cash from operating activities | (56,778) | (39,122) | |||
CAPEX | (142) | (195) | |||
Cash from investing activities | 11,876 | 6,926 | |||
Cash from financing activities | 45,996 | 396 | |||
FCF | (81,218) | (53,847) | |||
| Balance | |||||
Cash | 122,439 | 129,220 | |||
Long term investments | |||||
Excess cash | 122,439 | 129,220 | |||
Stockholders' equity | (163,184) | (88,367) | |||
Invested Capital | 273,805 | 216,271 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 26,332 | 24,472 | |||
Price | 22.63 -22.76% | 29.30 148.52% | |||
Market cap | 595,885 -16.90% | 717,033 149.14% | |||
EV | 475,216 | 589,993 | |||
EBITDA | (81,409) | (53,237) | |||
EV/EBITDA | |||||
Interest | 1,751 | ||||
Interest/NOPBT | |||||